Panitumumab is an immunoglobulin (Ig) G2 mAb that blocks EGFR; IgG2 mAb is FDA-approved for the treatment of patients with EGFR-expressing, metastatic colorectal cancer (42). This evidence concerns the gene EGFR and metastatic colorectal cancer.